Mesenchymal Stem Cell-Derived Exosome

Phase 3Cell therapy

MMert Ersan

Mesenchymal Stem Cell-Derived Exosome is one of 3 biologic programs targeting Skin Aging. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Skin AgingNot yet recruiting

Skin AgingPhase 3

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Skin Aging

#DrugCompanyPhaseTrials

Mesenchymal Stem Cell-Derived Exosome

MMert Ersan

Phase 3

1 2

Retin-a

VValeant Pharmaceuticals

Preclinical

—3

Botox

RRevance Therapeutics, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Not yet recruiting

Skin Aging

NCT07466953

Clinical

Trials by Indication[1]

Skin Aging1 trial

Objective Analysis of the Effects of Intradermally Administered Mesenchymal Stem Cell-Derived Suspended Exosome Therapy on Facial Skin Quality Using a Standardized Imaging System

Not yet recruiting·MMert Ersan·Phase 3·NCT07466953·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mesenchymal Stem Cell-Derived Exosome. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mesenchymal Stem Cell-Derived Exosome compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mesenchymal Stem Cell-Derived Exosome. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mert Ersan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 3[1]
Company: MMert Ersan

Mesenchymal Stem Cell-Derived Exosome

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Skin Aging1 trial

References

Drug Info

Quick Facts

Related News